Cantor Fitzgerald Reiterates Overweight on Beam Therapeutics, Maintains $56 Price Target
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Rick Bienkowski has reiterated an Overweight rating on Beam Therapeutics (NASDAQ:BEAM) and maintained a $56 price target.
August 29, 2023 | 3:39 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Beam Therapeutics' stock rating has been reiterated as Overweight by Cantor Fitzgerald, with a maintained price target of $56.
The reiteration of an Overweight rating by Cantor Fitzgerald indicates a positive outlook for Beam Therapeutics. The maintained price target of $56 suggests that the analyst believes the stock is still undervalued, which could lead to upward pressure on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100